Cerenome Announced Interim Data From Its Ongoing ReSPECT-LM Study Of Repeated Intraventricular Dosing Of REYOBIQ; No Dose-Limiting Toxicities Or Adverse Events Leading To Treatment Discontinuation Have Been Reported
Benzinga Newsdesk 1 day ago
News
Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted radiopharmaceuticals, and artificial
Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted radiopharmaceuticals, and artificial intelligence, today announced interim data from its ongoing ReSPECT-LM study of repeated intraventricular dosing of REYOBIQ™ (rhenium Re186 obisbemeda) in patients with leptomeningeal metastases (LM). The data were presented as a poster on November 13, 2026, during the Society for Neuro-Oncology (SNO) 31st Annual Meeting and Education Day.
The poster reports treatment exposure, safety, dosimetry, LM progression status, and cerebrospinal fluid (CSF) tumor-cell findings for the first 10 patients treated. No dose-limiting toxicities or adverse events leading to treatment discontinuation have been reported. To date, one patient has received three 26.4 mCi doses, for a total administered activity of 79.2 mCi. This exceeds the highest activity given as a single administration in the prior single-dose ReSPECT-LM study (75 mCi). Furthermore, imaging showed the radiation dose delivered to the LM compartment was consistent from one treatment to the next within each patient, varying by a median of 8%. These levels are consistent with previously reported Phase 1 single-dose data. Dose escalation is ongoing.
No LM progression was documented by the three- and six-month landmarks among evaluable patients (0/5 at each landmark), and progression was documented in 1 of 4 evaluable patients by nine months.
Interim ReSPECT-LM Findings
Of the 10 patients, six received 13.2 mCi per administration and four received 26.4 mCi per administration. Primary cancers included melanoma (4), breast cancer (3), non-small cell lung cancer (1), ovarian cancer (1), and neuroendocrine cancer (1). Nine patients had received prior LM therapy, and three were receiving concurrent systemic treatment.
Safety: No dose-limiting toxicities or adverse events leading to discontinuation have been observed. One patient had Grade 3 treatment-related nausea, which resolved within five days. The only serious adverse event, shortness of breath occurring in a single subject, was considered unrelated to treatment. All 10 patients had at least one treatment-emergent adverse event; the most common were nausea (60%), headache (40%), decreased lymphocyte count (40%), and decreased white blood cell count (40%).
Landmark LM progression findings: No LM progression was documented by three or six months among evaluable patients (0/5 at each landmark). By nine months, LM progression was documented in 1 of 4 evaluable patients. Evaluability was determined by principal investigator review of available records, based on documented progression on or before the landmark or adequate disease-assessment follow-up establishing LM status through that landmark. Patients with insufficient follow-up, or who died from primary disease before the landmark without prior LM progression, were excluded. These descriptive findings are not progression-free survival estimates.
CSF tumor-cell findings: Serial monitoring with Cerenome’s CNSide® documented tumor-cell reductions in individual patients. Three patients with detectable tumor cells at baseline later had samples with zero tumor cells/mL. Two of them remained at zero tumor cells/mL at their latest assessments, 9.2 and 2.3 months after the first dose, respectively. The third later had a rise in tumor-cell counts and MRI-confirmed LM progression, nearly 4 months after the third dose of REYOBIQ.
High cumulative absorbed doses: The first patient to complete three administrations at 26.4 mCi per dose received an estimated cumulative LM compartment absorbed dose of 207 Gy, with no dose-limiting toxicities. Five patients completing three administrations at the lowest dose level, 13.2 mCi per dose, received cumulative LM compartment absorbed doses of 85–137 Gy, again consistent with previously observed Phase 1 data.
Consistent repeat-dose delivery: In patients who received repeat administrations, the absorbed dose per mCi varied little from dose to dose (median within-patient coefficient of variation, 8%), as did the CSF effective half-life (12%). Dosimetry was consistent with the prior single-dose ReSPECT-LM experience, supporting the feasibility of repeat dosing. SPECT/CT imaging in the patient who completed three 26.4 mCi administrations showed a similar distribution of activity after each dose.
Low estimated bone marrow exposure: The median blood-derived marrow absorbed dose was 0.023 Gy per administration (range, 0.010–0.41 Gy). This low level of blood exposure is important to avoid potential cytopenias and further supports continued investigation of local LM compartmental delivery.
